Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical Trial

NCT05613426 is registered in ClinicalTrials.gov with Henan Institute of Cardiovascular Epidemiology as lead sponsor.

NCT NCT05613426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05613426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical Trial
Lead sponsor
Henan Institute of Cardiovascular Epidemiology
Phase
Phase 4
Overall status
Terminated
Start date
April 3, 2023
Completion date
May 16, 2026
Enrollment
119 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

st elevation myocardial infarction (stemi)